- Home
- MGLD vs GBIO Comparison
MGLD vs GBIO Comparison
Compare MGLD & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- GBIO
- Stock Information
- Founded
- MGLD 1996
- GBIO 2016
- Country
- MGLD United States
- GBIO United States
- Employees
- MGLD N/A
- GBIO N/A
- Industry
- MGLD Finance/Investors Services
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- GBIO Health Care
- Exchange
- MGLD Nasdaq
- GBIO Nasdaq
- Market Cap
- MGLD 44.8M
- GBIO 41.2M
- IPO Year
- MGLD N/A
- GBIO 2020
- Fundamental
- Price
- MGLD $1.03
- GBIO $5.08
- Analyst Decision
- MGLD
- GBIO Buy
- Analyst Count
- MGLD 0
- GBIO 4
- Target Price
- MGLD N/A
- GBIO $10.67
- AVG Volume (30 Days)
- MGLD 9.5K
- GBIO 74.3K
- Earning Date
- MGLD 11-07-2025
- GBIO 11-05-2025
- Dividend Yield
- MGLD N/A
- GBIO N/A
- EPS Growth
- MGLD N/A
- GBIO N/A
- EPS
- MGLD N/A
- GBIO N/A
- Revenue
- MGLD $29,207,000.00
- GBIO $15,270,000.00
- Revenue This Year
- MGLD N/A
- GBIO N/A
- Revenue Next Year
- MGLD N/A
- GBIO N/A
- P/E Ratio
- MGLD N/A
- GBIO N/A
- Revenue Growth
- MGLD N/A
- GBIO N/A
- 52 Week Low
- MGLD $0.64
- GBIO $3.00
- 52 Week High
- MGLD $2.10
- GBIO $25.70
- Technical
- Relative Strength Index (RSI)
- MGLD 50.10
- GBIO 31.13
- Support Level
- MGLD $0.99
- GBIO $5.10
- Resistance Level
- MGLD $1.06
- GBIO $6.47
- Average True Range (ATR)
- MGLD 0.03
- GBIO 0.26
- MACD
- MGLD -0.01
- GBIO -0.13
- Stochastic Oscillator
- MGLD 39.13
- GBIO 9.74
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.